Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.63 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554681 | 0.83 | ALDH1A1 (0.43) | LPLLIPGALDH1A1 | |
| SCHEMBL3138179 | 0.79 | LPL (0.90) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL1421621 | 0.78 | LPL (0.77) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL634209 | 0.77 | KEAP1 (0.57) | LPLLIPGENPP2MGLL | |
| SCHEMBL1997891 | 0.77 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL202958 | 0.77 | LPL (0.69) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL10907937 | 0.77 | DRD2 (0.55) | ENPP2MGLL | |
| SCHEMBL28980647 | 0.76 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL28980712 | 0.76 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 | |
| SCHEMBL3146386 | 0.76 | LIPG (1.00) | LPLLIPGENPP2MGLLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013782-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9708570-B2 | Organic compounds | Givaudan, S.A. (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20160369205-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-12-22 | — | — | US | disclosed |
| EP-3013782-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207205-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014205782-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369205-A1 | ORGANIC COMPOUNDS | PAH, AQP3, HPD | LPL 1397/4885LIPG 1560/4885ENPP2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.